SciELO - Scientific Electronic Library Online

vol.75 issue2Evolution of the socio-economic differences in the use and accessibility of health services in Spain between 1987 and 1995-97Secondary prevention of ischemic heart disease at the lipid-related level in primary care in Aragon. Assessment study PRECIAR I. author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Revista Española de Salud Pública

On-line version ISSN 2173-9110Print version ISSN 1135-5727


SILES GUTIERREZ, Miguel; GOLDARACENA TANCO, Margarita; AVILA MUNOZ, Luisa  and  SANCHEZ-EZNARRIAGA, Belén Crespo. Lipid-reducing drug consumption in Spain, 1987-2000. Rev. Esp. Salud Publica [online]. 2001, vol.75, n.2, pp.129-142. ISSN 2173-9110.

BACKGROUND: Lipid-reducing drugs are currently among those most used and which have the greatest impact on the drug spending of the Spanish National Health Care System. At the same time, constant changeovers are taking place from one type of molecule to another within this group.  METHODS: A study was made of all of the Spanish National Health Care System prescriptions filled from the treatment subgroup B04A "Lipid-Reducing Preparations" nationwide throughout the 1987-2000 period. The different active ingredients have been grouped according to the subgroups of the Anatomical Therapeutic Chemical Classification. The measurement parameters employed were the number of packages, the economic cost, the number of Defined Daily Doses (DDD) and the Treatment/Day Cost (TDC).  RESULTS: Lipid-reducing drug consumption for the timeframe in question totals 389,133,314,142 pesetas (2,338,738,320 euros) and 2,580,179,790 DDD. Consumption rose annually, ranging from 4,504,321,869 pesetas in 1987 to 71,389,377,528 in 2000; and from 63,594,576 to 420,878,797 DDD. The TDC rose, in turn from 71 to 170 pesetas. The subgroup showing the highest consumption was that of the statin drugs, totalling 73.4% of the total consumption by cost and 54.8% of the number of DDD's, showing a trend toward further growth. CONCLUSIONS: Lipid-reducing drugs have undergone a noticeable, constant rise throughout the timeframe under analysis, not only regarding the price, but also the number of DDD's. Statin drugs having started to be used has modified the guidelines of use for this group.

Keywords : Cholesterol; Lipid-reducing drug; Drug Use Studies; DDD's; DHD; TDC.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License